May 22, 2025
Cellenkos Inc. and King Faisal Specialist Hospital & Research Centre, Sign Strategic MOU to Advance T Regulatory Cell Therapies for Unmet Diseases
Nov 07, 2024
Cellenkos Announces Oral Presentation at ASH Annual Meeting 2024 Highlighting Phase 1b Clinical Data of CK0804 in Myelofibrosis
Apr 01, 2024
Cellenkos® enters into Sponsored Research Agreement with Icahn School of Medicine at Mount Sinai, New York.
Feb 19, 2024
Cellenkos Approved to Proceed with CK0803 Neurotrophic T regulatory Cell therapy to Treat Second Cohort in ALS Trial
Jan 19, 2024
Michael E. DeBakey VA Medical Center VA Hospital announces New Cell Therapy Clinical Trial for Amyotrophic Lateral Sclerosis
Jun 02, 2020
Cellenkos® Inc. Announces FDA Clearance to Initiate Phase 1 Double- Blinded, Randomized, Placebo-Controlled Trial of Cryopreserved Cord Blood-Derived T-Regulatory Cells (CK0802) for Treatment of COVID-19 Associated Acute Respiratory Distress Syndrome
Mar 17, 2020
Cellenkos Inc. Focuses on the Development of Cell-Therapy for Treatment of COVID-19 Mediated Acute Respiratory Distress Syndrome (CoV-ARDS)
Jan 08, 2019
Cellenkos, Inc. Appoints Elizabeth Read as Chief Technology Officer, Adding Technology and Regulatory Affairs Expertise to its Executive Team
Oct 16, 2018
Cellenkos, Inc. Announces FDA Clearance of Investigational New Drug Application for CK0801 for Treatment-Resistant Guillain-Barré Syndrome
Jun 22, 2018
Cellenkos, Inc. Announces Neuroinflammation Research Collaboration with The University of Texas Health Science Center at Houston
Jun 10, 2018
Cellenkos(TM), Inc. Announces FDA Clearance of Investigational New Drug Application for CK0801 for Bone Marrow Failure Syndromes
Apr 16, 2018
Golden Meditech's Associate, Cellenkos Names Alick Sun as Corporate & Business Development SVP
Apr 13, 2018
Cellenkos, Inc. Announces Alick Sun as Senior Vice President for Corporate and Business Development
Feb 07, 2018
Golden Meditech Announces FDA Registration of GMP Manufacturing Facility by its Associate, Cellenkos, Inc.